Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Dose-Response Biomarker Study of Brexpiprazole Treatment in PTSD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Participants will be 18-65 years of age.~* All subjects will be evaluated by physical examination, ECG, standard blood chemistry, hematologic labs, toxicology testing, and urinalysis at baseline and end of study. Results of these studies must demonstrate a lack of clinically significant abnormalities prior to enrollment. If results are outside of the normal reference range the study physician will be consulted to assess if clinically significant.~* Subjects will need to satisfy DSM-5 criteria for PTSD and receive a CAPS-5 score of 40 or greater on testing for study enrollment.~* Subjects will need to be free of psychotropic medications or treatments that could impact results of this study as deemed by the PI for at least 1 week.~* If the subject's primary psychiatrist or treating primary care physician are providing the subject with psychotropic medications they will be notified and a discussion about tapering current psychotropic medications prior to study enrollment will occur.~Exclusion Criteria:~1. Subjects will be excluded if they have significant medical or neurologic conditions (other than mild to moderate TBI), specifically seizures, or movement disorders,~2. have substance abuse within 12 months of study enrollment, substance dependence within past three months, per DSM-5 criteria (excluding caffeine and nicotine). The absence of substance use will be determined by self-report and confirmed by the results of urine toxicology at screening.~3. Women who are pregnant, breast-feeding, or planning to become pregnant while enrolled in this study will also be excluded.~4. Subjects with a history of severe drug allergy or hypersensitivity, or known hypersensitivity to the Brexpiprazole or its ingredients.~5. The subject has a history of tardive dyskinesia.~6. The subject has clinically significant extrapyramidal symptoms (EPS) including akathisia.~7. The subject has epilepsy or a history of seizures, except for a single seizure episode (e.g., childhood febrile seizure, post traumatic, or alcohol withdrawal).~8. The subject has chronic, uncontrolled, or unstable clinically relevant medical conditions Including:~   * Uncontrolled hypertension defined as blood pressure greater than 180/90~  * Hypotension defined as a blood pressure less than 90/60~  * Moderate to severe hepatic impairment (Child-Pugh score ≥7)~  * Moderate, Severe or End-Stage Renal Impairment (CrCL \<60ml/min)~  * Known CYP2DG Poor Metabolizers~  * Heart failure NYHA Class III or IV~  * Diabetes mellitus or HbA1c greater than 5.7% (which defines pre-diabetes)~  * Hypertriglyceridemia defined as triglycerides greater than 200mg/dL~  * Low white blood cell count (below lower range of normal)~  * History of leukopenia or neutropenia~  * Arrhythmia with heart rate greater than 100bpm~  * Myocardial infarction in the past 6 months~  * Cerebrovascular accident in the past 6 months~  * Recurrent syncope~  * Seizure disorder~  * Currently receiving treatment for malignancy~  * QTc interval of greater than 450ms on electrocardiogram~9. The subject has a neurodegenerative disorder (Alzheimer disease, Parkinson's disease, multiple sclerosis, Huntington disease, etc.).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Brexpiprazole 2mg (Type: EXPERIMENTAL): Subjects will be titrated to this dose of brexpiprazole for 6 weeks.
- Brexpiprazole 4mg (Type: EXPERIMENTAL): Subjects will be titrated to this dose of brexpiprazole for 6 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Subjects will be titrated to this dose of placebo for 6 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).